Affiliation:
1. Sanofi‐Aventis Deutschland GmbH, R&D Large Molecules Research Frankfurt am Main Germany
2. Institute for Developmental Biology and Neurobiology (IDN) Johannes Gutenberg University Mainz Germany
Abstract
IgMs are the first antibodies produced by the immune system upon encounter of a possible pathogen and are one of five antibody subclasses in humans. For IgG, the most intensively studied antibody class, the N‐linked glycosylation site located in the Fc‐domain is directly involved in high affinity binding to the respective receptors and initiation of corresponding immune response. IgM molecules have five N‐glycosylation sites and one N‐glycosylation site in the J‐chain, which can be incorporated in IgM or IgA molecules. There is only limited knowledge available concerning the function of these N‐glycosylations in IgMs. To address this question, we produced IgM molecules lacking a particular N‐glycosylation site and tested these variants as well as IgA molecules for binding to the known receptors: the polymeric immunoglobulin receptor (pIgR), the dual receptor for IgA and IgM, FcαμR, and the specific receptor for IgM, FcμR. The single glycosylation sites did not show an impact on expression and multimerization, except for variant N402Q, which could not be expressed. In SPR measurements, no major impact on the binding to the receptors by particular glycosylation sites could be detected. In cellular assays, deglycosylated variants showed some alterations in induction of CDC activity. Most strikingly, we observed also binding of IgA to the FcμR in the same affinity range as IgM, suggesting that this might have a physiological role. To further substantiate the binding of IgA to FcμR we used IgA from different origins and were able to confirm binding of IgA preparations to the FcμR.